Cannabis Science CEO Launches Raymond C. Dabney University (RCDU) and Releases Schematics for Approx. 40 Acres (1.5 Million Sq. Ft.) With the McDermitt Indian Reservation for the Nevada Drug Development Complex
LOS ANGELES, CA--(Marketwired - May 6, 2016) - Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. company specializing in the development of cannabis-based medicines, is proud to unveil schematics for its first drug development complex. Cannabis Science CEO releases Raymond C. Dabney University out of California, which is the cornerstone of the Nevada Drug Development Complex. The complete property development deal is approximately 40 acres, spanning more than 1.5 million square feet located in McDermitt, Nevada.
The 40-acre community development project is based on a deal signed by RCDU, AEIG legal group and CBIS with the McDermitt Indian Reservation to develop land. The focal point of the community development project is the Raymond C. Dabney University, a fully accredited school of Law, Business, and Medicine. The Goal of Raymond C. Dabney University (RCDU) is to "provide financially challenged communities an affordable opportunity to acquire a quality legal education beginning with a structured and regulated program in Law."
"This whole experience has been a serious eye opening look into the future, launching the University, planning with Chief Bill, working with our outstanding legal group, and of course my team at Cannabis Science. We have now certainly made it to the next level and are growing much faster than we initially anticipated. The business model we have created with the McDermitt Tribe is something of a wonder when you do the math: let's just say potentially seeing over $10-20 million per month running through the system is what I'd call a serious economic stimulus package for all of us. The most compelling things are the jobs we are creating, the education we are providing, and the sense of hope for individuals like me who have never had this type of educational or job opportunity given to them for whatever reason. To be clear, this is the first of many hybrid University Medical complex communities we will be building. As time and resources permit, we will be offering University package courses in major cities across the United States and other countries, including but not limited to Canada, Europe, Africa, and Asia," stated Cannabis Science, Inc. President & CEO, Co-Founder, Mr. Raymond C. Dabney.
Please visit www.rcdu.com for an initial run down of Law course curriculum and tuition fees. The initial Mission of Raymond C. Dabney University is to provide to working adults of the community an affordable opportunity to acquire a quality legal education within a structured and regulated program in law leading to the degree of Juris Doctor.
RCDU will be providing free scholarships and additionally subsidized education packages for the Tribe Members of the Community. In exchange for and in addition to the land, the tribe will provide RCDU with a University building, lab space, and medical clinic facilities. The intent is to create a self-sustaining community of academia, which allows business opportunities, medical advancement, and legal progress to thrive.
RCDU and its legal group will work closely with Cannabis Science and the McDermitt Tribe to manage and operate the University and Medical Complex. With approximately 40 acres to work with, it is designed to be a completely vertically integrated operations model providing hundreds of jobs for the community, educational, medical, construction, as the list goes on, there will be plenty of jobs for all.
About Cannabis Science, Inc.
Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.
Forward-Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a 'safe harbor' for forward-looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company are detailed from time to time in the company's reports filed with the Securities and Exchange Commission.